Cellular and Molecular Neurobiology

, Volume 27, Issue 5, pp 609–639

Cognitive Deficits in Schizophrenia: Focus on Neuronal Nicotinic Acetylcholine Receptors and Smoking

Original Paper

DOI: 10.1007/s10571-007-9149-x

Cite this article as:
Ochoa, E.L.M. & Lasalde-Dominicci, J. Cell Mol Neurobiol (2007) 27: 609. doi:10.1007/s10571-007-9149-x

Abstract

Patients with schizophrenia present with deficits in specific areas of cognition. These are quantifiable by neuropsychological testing and can be clinically observable as negative signs. Concomitantly, they self-administer nicotine in the form of cigarette smoking. Nicotine dependence is more prevalent in this patient population when compared to other psychiatric conditions or to non-mentally ill people. The target for nicotine is the neuronal nicotinic acetylcholine receptor (nAChR). There is ample evidence that these receptors are involved in normal cognitive operations within the brain. This review describes neuronal nAChR structure and function, focusing on both cholinergic agonist-induced nAChR desensitization and nAChR up-regulation. The several mechanisms proposed for the nAChR up-regulation are examined in detail. Desensitization and up-regulation of nAChRs may be relevant to the physiopathology of schizophrenia. The participation of several subtypes of neuronal nAChRs in the cognitive processing of non-mentally ill persons and schizophrenic patients is reviewed. The role of smoking is then examined as a possible cognitive remediator in this psychiatric condition. Finally, pharmacological strategies focused on neuronal nAChRs are discussed as possible therapeutic avenues that may ameliorate the cognitive deficits of schizophrenia.

Keywords

SchizophreniaNicotinic receptors

Abbreviations

ACh

Acetylcholine

AES

Apathy Evaluation Scale

αBgt

α-Bungarotoxin

BPRS

Brief Psychiatric Rating Scale

DHβE

Dihydro-β-erythroidine

DMPP

1,1-dimethyl-4-phenylpiperazinium

FDA

Food and Drug Administration

GABA

Gamma aminobutyric acid

5-HT

5-Hydroxytryptamine

MATRICS

Measurement and Treatment Research to Improve Cognition in Schizophrenia

NIMH

National Institute of Mental Health

MCC

Methylcarbamylcholine

nAChR

Nicotinic acetylcholine receptor

NMDA

N-methyl-d-aspartic acid

OL

Open Label

PANSS

Positive and Negative Symptom Scale for Schizophrenia

PKA

Protein kinase A

PKC

Protein kinase C

RBANS

Repeatable Battery for the Assessment of Neuropsychological status

RCFT

Rey Complex Figure Test

RCT

Randomized Controlled Trial

SANS

Scale for the Assessment of Negative Symptms in Schizoprenia

SCIP

Scale for the Assessment of Cognitive Impairment in Psychosis

SGA

Second generation antipsychotics

SN

Substantia nigra

TMA

Tetramethylammonium

VTA

Ventral tegmental area

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Department of PsychiatryUniversity of California at DavisSacramentoUSA
  2. 2.Department of BiologyUniversity of Puerto RicoSan JuanPuerto Rico